Answers are grounded in this paper and cite their sources.
Cabozantinib significantly improved overall survival compared with everolimus in previously treated patients with advanced RCC with consistent results after long-term follow-up.
No takes yet. Share an insight, caveat, or question.
Motzer et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: